1. Blood graft and outcome after autologous stem cell transplantation in patients with primary central nervous system lymphoma
- Author
-
Partanen, A. (Anu), Kuittinen, O. (Outi), Turunen, A. (Antti), Valtola, J. (Jaakko), Pyörälä, M. (Marja), Kuitunen, H. (Hanne), Vasala, K. (Kaija), Kuittinen, T. (Taru), Mantymaa, P. (Pentti), Pelkonen, J. (Jukka), Jantunen, E. (Esa), Varmavuo, V. (Ville), Partanen, A. (Anu), Kuittinen, O. (Outi), Turunen, A. (Antti), Valtola, J. (Jaakko), Pyörälä, M. (Marja), Kuitunen, H. (Hanne), Vasala, K. (Kaija), Kuittinen, T. (Taru), Mantymaa, P. (Pentti), Pelkonen, J. (Jukka), Jantunen, E. (Esa), and Varmavuo, V. (Ville)
- Abstract
Background: Autologous stem cell transplantation (auto-SCT) is a treatment option for patients with primary central nervous system lymphoma (PCNSL). Methods: In this prospective multicenter study, the effects of blood graft cellular content on hematologic recovery and outcome were analyzed in 17 PCNSL patients receiving auto-SCT upfront. Results: The infused viable CD34⁺ cell count > 1.7 × 10⁶/kg correlated with more rapid platelet engraftment (10 vs. 31 days, P = 0.027) and with early neutrophil recovery (day + 15) (5.4 vs. 1.6 × 10⁹/L, P = 0.047). A higher number of total collected CD34⁺ cells > 3.3 × 106/kg infused predicted worse 5-year progression-free survival (PFS) (33% vs. 100%, P = 0.028). In addition, CD3⁺CD8⁺ T cells > 78 × 10⁶/kg in the infused graft impacted negatively on the 5-year PFS (0% vs. 88%, P = 0.016). Conclusions: The cellular composition of infused graft seems to impact on the hematologic recovery and PFS post-transplant. Further studies are needed to verify the optimal autograft cellular content in PCNSL.
- Published
- 2021